Jeffrey A. Baumel
Dentons
Articles
SEC adopts pay ratio rule
USA - September 28 2015 The US Securities and Exchange Commission (SEC) has adopted a final rule to implement the requirement of Section 953(b) of the Dodd-Frank Wall Street…
SEC proposals for securities crowdfunding under Title III of the JOBS Act
USA - January 23 2014 The U.S. Securities and Exchange Commission (SEC) has proposed rules to implement the provisions of Title III of the Jumpstart Our Business Startups…
U.S. v. Caronia: a rift in prosecution of off-label promotion?
USA - December 12 2012 A recent decision by the Second Circuit Court of Appeals is being hailed as a potential "game-changing" defeat for federal prosecutors in their pursuit of criminal indictments and civil False Claims Act cases predicated upon the "off-label" promotion and marketing of FDA-approved pharmaceutical drugs and medical devices.
Sean C. Cenawood, Peg Donahue Hall, John L. Cleary II, Gadi Weinreich
Supreme Court rejects statistical significance requirement in 10b-5 action involving life science company's failure to disclose adverse event reports
USA - April 4 2011 On March 22, 2011, the Supreme Court of the United States issued an important opinion for life sciences companies in Matrixx Initiatives, Inc., et. al. v. Siracusano et. al., a class action securities lawsuit involving Matrixx's leading product, Zicam Cold Remedy.
SEC adopts final "say on pay," "say on frequency" and "say on golden parachutes" rules
USA - January 28 2011 In our 2011 Proxy Season Update dated January 12, 2011 (available here) we provided a detailed discussion of the SEC's new requirements that US public companies submit "Say on Pay" and "Say on Frequency" proposals to advisory votes of their shareholders.
